Cassava Sciences, Inc. (SAVA)
After hours:
| Previous Close | 45.19 |
| Open | 46.00 |
| Bid | 45.91 x 1000 |
| Ask | 45.89 x 2900 |
| Day's Range | 43.32 - 46.89 |
| 52 Week Range | 13.84 - 100.00 |
| Volume | |
| Avg. Volume | 3,465,241 |
| Market Cap | 1.852B |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 13, 2012 |
| 1y Target Est | 69.00 |
- Zacks
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $31.04, moving -1.71% from the previous trading session.
- GlobeNewswire
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York. Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log into www.hcwevents.com t
- GlobeNewswire
No Evidence of Data Manipulation in Science Publication on Simufilam
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer's Disease (JPAD) that there is no convincing evidence to support allegations of data manipulation in a 2020 paper on simufilam co-authored by the Company’s personnel and its science collaborators. JPAD communicated the following statement to the Company on Monday, August 15th
